Alzheimer’s Disease: Role of Energy Metabolism and Treatment of Symptoms

  • D. M. Bowen
  • P. T. Francis
  • S. L. Lowe
  • M. N. Pangalos
  • A. W. Procter
  • J. E. Steele
Conference paper


The formation and accumulation of neurofibrillary tangles within cortical pyramidal neurones [28], has been considered the major direct cause of nerve cell degeneration. At present the excitement of the work on the structure of betaamyloid protein in senile plaques, and the implications from knowledge of the cDNA sequence of its precursor, has overshadowed the tangle and pyramidal cell. For example, it has been suggested that understanding biochemical changes occurring after the amyloid precursor protein has been synthesized may eventually provide treatment [6]. The disease has also often been approached optimistically as purely a genetic disorder involving chromosome 21, yet research fails to establish this for families where the disease appears late in life (e.g., [19]). It is generally accepted that there is a role for genes and amyloid-related proteins in pathogenesis, but these are unlikely to be the only factors, so a broader view is necessary because it is likely that the clinical syndrome results from a series of different events over a long period [3].


Positron Emission Tomography Pyramidal Cell Amyloid Precursor Protein Neurofibrillary Tangle Excitatory Amino Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beckmann RP, Mizzen LA, Welch WJ (1990) Interaction of HSP 70 with newly synthesized proteins: implications for protein folding and assembly. Science 248:850–853PubMedCrossRefGoogle Scholar
  2. 2.
    Bowen DM, Francis PT (1990) Neurochemistry, neuropharmacology and aetiological factors in Alzheimer’s disease. Seminar in the Neurosciences 2:101–108Google Scholar
  3. 3.
    Bowen DM, Beyreuther K, Cross AJ et al. (1988) Group report. Cell injury: molecular biology and genetic basis. In: Henderson AS Henderson JH (eds), Etiology of dementia of Alzheimer’s type. Wiley, Chichester, pp 165–176Google Scholar
  4. 4.
    Bowen DM, Francis PT, Lowe SL, Pangalos MN, Procter AW, Steele JE (1989) Pyramidal neuron loss and “glycine-site therapy”: a need for an animal model and study in late-life depression. Neurobiol Aging 10:616–618PubMedCrossRefGoogle Scholar
  5. 5.
    Bowen DM, Cross AJ, Francis PT, Green AR, Lowe SL, Procter AW, Steele JE, Stratmann GC (1990) Distribution of neurochemical deficits in Alzheimer’s disease. In: Rapoport SI, Petit H, Leys D, Christen Y (eds) Research and perspectives in Alzheimer’s disease. Springer, Berlin Heidelberg New York, pp 41–51Google Scholar
  6. 6.
    Caputo CB, Salama AI (1989) Authors’ response to commentaries. Neurobiol Aging 10:451–462PubMedCrossRefGoogle Scholar
  7. 7.
    Esiri MM, Pearson RCA, Steele JE et al. (1990) A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 53:161–165PubMedCrossRefGoogle Scholar
  8. 8.
    Francis PT, Bowen DM (1989) Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence. Can J Neurol Sci 16:504–510PubMedGoogle Scholar
  9. 9.
    Greenamyre JT, Young AB (1989) Author’s response to commentaries. Neurobiol Aging 10:618–620CrossRefGoogle Scholar
  10. 10.
    Hood WF, Compton RP, Monahan JB (1989) D-Cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91–95PubMedCrossRefGoogle Scholar
  11. 11.
    Hoyer S, Oesterreich K, Wagner O (1988) Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 235:143–148PubMedCrossRefGoogle Scholar
  12. 12.
    Kelley M, Kowall N (1989) Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer’s disease. Brain Res 501:392–396PubMedCrossRefGoogle Scholar
  13. 13.
    Leung TKC, Rajendran MY, Monfries C, Hall C, Lim L (1990) The human heat-shock protein family: expression of a novel heat-inducible HSP70 (HSP70B’) and isolation of its cDNA and genomic DNA. Biochem J 267:125–132PubMedGoogle Scholar
  14. 14.
    Lowe SL, Francis PT, Procter AW et al. (1988) Gamma aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain 111:785–799PubMedCrossRefGoogle Scholar
  15. 15.
    Lowe SL, Bowen DM, Francis PT, Neary D (1990) Antemortem cerebral amino acid concentrations indicate selective degeneration of glutmate-enriched neurones in Alzheimer’s disease. Neuroscience 38:571–577PubMedCrossRefGoogle Scholar
  16. 16.
    Martin JB, Beal MF, Mazurek M et al. (1988) Some observations on the significance of neurotransmitter changes in Alzheimer’s disease. In: RD Terry (ed) Aging and the brain Raven, New York, pp 129–148Google Scholar
  17. 17.
    McCabe BJ, Horn G (1988) Learning and memory; regional changes in N-methyl-D-aspartate receptors in the chick brain. Proc Natl Acad Sci USA 85: 2849–2855PubMedCrossRefGoogle Scholar
  18. 18.
    Neary D, Snowden JS, Mann DMA et al. (1986) Alzheimer’s disease: a correlative study. J Neurol Neurosurg Psychiatry 49:229–237PubMedCrossRefGoogle Scholar
  19. 19.
    Pericak-Vance, MA, Yamaoka LH, Haynes CS et al. (1988) Genetic linkage studies in Alzheimer’s Disease families. Exp Neurol 102:271–279PubMedCrossRefGoogle Scholar
  20. 20.
    Procter AW, Palmer AM, Francis PT et al. (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer’s disease. J Neurochem 50:790–802PubMedCrossRefGoogle Scholar
  21. 21.
    Procter AW, Wong EHF, Stratmann GC et al. (1989) Reduced glycine stimulation of [3H] MK801 binding in Alzheimer’s disease. J Neurochem 53:698–704PubMedCrossRefGoogle Scholar
  22. 22.
    Reinikainen KJ, Paljarvi L, Huuskonen M et al. (1988) A postmortem study of noradrenergic serotonergic and GABAergic neurones in Alzheimer’s disease. J Neurol Sci 84:101–116PubMedCrossRefGoogle Scholar
  23. 23.
    Rhencrona S, Rosen I, Siesjo BK (1981) Brain lactic acidosis and ischemic cell damage. 1. Biochemistry and neurophysiology. J Cereb Blood Flow Metab 1:297–311CrossRefGoogle Scholar
  24. 24.
    Selkoe DJ (1990) Deciphering Alzheimer’s disease: the amyloid precursor protein yields new clues. Science 248:1058–1060PubMedCrossRefGoogle Scholar
  25. 25.
    Siesjo BK, Bengtsson F (1989) Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression; a unifying hypothesis. J Cereb Blood Flow Metab 9:227–240CrossRefGoogle Scholar
  26. 26.
    Sims NR, Bowen DM, Neary D, Davison AN (1983) Metabolic processes in Alzheimer’s disease: adenine nucleotide content and production of 14CO2 from [U14C]glucose in vitro in human neocortex. J Neurochem 41:1329–1334PubMedCrossRefGoogle Scholar
  27. 27.
    Sims NR, Finegan JM, Blass JP et al. (1987) Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 436:30–38PubMedCrossRefGoogle Scholar
  28. 28.
    Spillantini MG, Goedert M, Jakes R, Klug A (1990) Topographical relationship between β-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Nat Acad Sci USA 87:3952–3956PubMedCrossRefGoogle Scholar
  29. 29.
    Watson GB, Bolanowski MA, Baganoff MP, Deepeler CL, Lanthorn TH (1990) D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed Xenopus oocytes. Brain Res 510:158–169PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • D. M. Bowen
    • 1
  • P. T. Francis
    • 1
  • S. L. Lowe
    • 1
  • M. N. Pangalos
    • 1
  • A. W. Procter
    • 1
  • J. E. Steele
    • 1
  1. 1.Miriam Marks Department of NeurochemistryInstitute of Neurology (Queen Square)LondonUK

Personalised recommendations